No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease

Thrombosis and Haemostasis

Volumn 96, Issue 5, 2006, Pages 660-664

  Solheim, Svein ^a   Pettersen, Alf Aage ^a   Arnesen, Harald ^a   Seljeflot, Ingebjørg ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Antiplatelet agents; Atherosclerosis; Inflammation; Randomized trial

Indexed keywords

ACETYLSALICYLIC ACID; ALBYL E; ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CD40 LIGAND; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DISEASE MARKER; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; TREATMENT DURATION;

EID: 33751224446     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-06-0337     Document Type: Article

References (42)

1. Carlos T, Kovach N, Schwartz B, et al. Human monocytes bind to two cytokine-induced adhesive ligands on cultured human endothelial cells: endothelial-leukocyte adhesion molecule-1 and vascular cell adhesion molecule-1. Blood 1991; 77: 2266-71.
2. Graber N, Gopal TV, Wilson D, et al. T cells bind to cytokine-activated endothelial cells via a novel, inducible sialoglycoprotein and endothelial leukocyte adhesion molecule-1. J Immunol 1990; 145: 819-30.
3. Jang Y, Lincoff AM, Plow EF, et al. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994; 24: 1591-601.
4. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
5. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488-96.
6. Bevilacqua MP, Pober JS, Mendrick DL, et al. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 1987; 84: 9238-42.
7. Frostegard J, Wu R, Haegerstrand A, et al. Mononuclear leukocytes exposed to oxidized low density lipoprotein secrete a factor that stimulates endothelial cells to express adhesion molecules. Atherosclerosis 1993; 103: 213-9.
8. Thornhill MH, Wellicome SM, Mahiouz DL, et al. Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and -independent binding mechanisms. J Immunol 1991; 146: 592-8.
9. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-8.
10. Willerson JT. Systemic and local inflammation in patients with unstable atherosclerotic plaques. Prog Cardiovasc Dis 2002; 44: 469-78.
11. Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999; 99: 2079-84.
12. Lindmark E, Diderholm E, Wallentin L, et al. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. J Am Med Assoc 2001; 286: 2107-13.
13. Ridker PM, Rifai N, Pfeffer M, et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149-53.
14. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72.
15. Skoog T, Dichtl W, Boquist S, et al. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J 2002; 23: 376-83.
16. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109 (Suppl 1):112-10.
17. Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. Cardiol Clin 2003; 21: 315-25.
18. Boisvert WA. Modulation of atherogenesis by chemokines. Trends Cardiovasc Med 2004; 14: 161-5.
19. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
20. Pinderski Oslund LJ, Hedrick CC, Olvera T, et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999; 19: 2847-53.
21. Tedgui A, Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ Res 2001; 88: 877-87.
22. Seljeflot I, Hurlen M, Solheim S, et al. Serum levels of interleukin-10 are inversely related to future events in patients with acute myocardial infarction. J Thromb Haemost 2004; 2: 350-2.
23. Viles-Gonzalez JF, Anand SX, Valdiviezo C, et al. Update in atherothrombotic disease. Mt Sinai J Med 2004; 71: 197-208.
24. Wagner DD. New links between inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2005; 25: 1321-4.
25. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
26. Kinlay S, Schwartz GG, Olsson AG, et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIR-ACL) Study. Circulation 2004; 110: 386-91.
27. Schonbeck U, Varo N, Libby P, et al. Soluble CD40L and cardiovascular risk in women. Circulation 2001; 104: 2266-8.
28. Ballantyne CM, Nambi V. Markers of inflammation and their clinical significance. Atheroscler Suppl 2005; 6: 21-9.
29. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103: 491-5.
30. Solheim S, Arnesen H, Eikvar L, et al. Influence of aspirin on inflammatory markers in patients after acute myocardial infarction. Am J Cardiol 2003; 92: 843-5.
31. Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999; 100: 793-8.
32. Pettersen AA, Seljeflot I, Abdelnoor M, et al. Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J 2004; 38: 353-6.
33. Weber C, Erl W, Pietsch A, et al. Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation 1995; 91: 1914-7.
34. Klinkhardt U, Graff J, Harder S. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Pharmacol Ther 2002; 71: 176-85.
35. Quinn MJ, Bhatt DL, Zidar F, et al. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutancous coronary intervention. Am J Cardiol 2004; 93: 679-84.
36. Schober A, Manka D, von HP, et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002; 106: 1523-9.
37. Muir KW, Weir CJ, Alwan W, et al. C-reactive protein and outcome after ischemic stroke. Stroke 1999; 30: 981-5.
38. Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004; 25: 166-81.
39. Hermann A, Rauch BH, Braun M, et al. Platelet CD40 ligand (CD40L) - subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001; 12: 74-82.
40. Henn V, Steinbach S, Buchner K, et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98: 1047-54.
41. Klinkhardt U, Harder S. Flow cytometric measurement of platelet-leukocyte aggregates: a possible target to monitor platelet function? Semin Thromb Hemost 2005; 31: 400-3.
42. Almuti K, Rimawi R, Spevack D, et al. Effects of statins beyond lipid lowering: Potential for clinical benefits. Int J Cardiol 2006; 109: 7-15.